Poplar Therapeutics

Homepage

Founded 2024 · $95.0M raised

Founded
2024
Total Funding
$95.0M
Last Round
$45.0M Extension RoundMar 2026
Rounds
2

About

Poplar Therapeutics is a clinical-stage immunology company developing a new class of anti-IgE therapy to challenge convention in allergic disease treatment. The company is on a mission to create the next generation of anti-IgE medicines so that patients can live free of fear. Its lead program, PHB-050, is a new class of anti-IgE therapy for multiple atopic conditions.

Summary

Poplar Therapeutics is a Biotech company, founded in 2024. It has raised $95.0M in total across 2 rounds, most recently a $45.0M Extension Round in Mar 2026. Investors include SR One, Vida Ventures and Janus Henderson Investors.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Extension RoundExtension RoundMar 2026
$45.0M

Sign up to see all 2 events

Funding: Series A through Extension Round. Amounts, valuations, and investors where available.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Poplar Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/poplar-therapeutics"><img src="https://indexed.vc/api/badge/company/poplar-therapeutics" alt="Poplar Therapeutics on Indexed.vc" width="260" height="76" /></a>